phrykt

ARS Pharmaceuticals, Inc. (SPRY): who owns it and who trades it

As of Nov 16, 2026, SPRY insiders reported 2 open-market sales worth $284K and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Eric Karas (Chief Commercial Officer), with $250K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling ARS Pharmaceuticals

From the latest filings

Overall: more buying than selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns SPRY

205 funds and institutions reported SPRY shares worth $731M at the end of Q2 2026, about 92% of the company. The largest holder is Ra Capital Management, L.P. with 10.9%.

Funds and institutions (13F) 92%Everyone else 8%

10 largest owners, by share of the company

Ra Capital Management, L.P.10.9%
Rubric Capital Management LP8.6%
Orbimed Advisors LLC8.3%
Deerfield Management Company, L.P.7.6%
BlackRock, Inc.5.3%
Tyro Capital Management LLC4.5%
Aberdeen Group plc4.2%
SR One Capital Management, LP4.0%
State Street Corp3.8%
Capital World Investors2.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.10.86M10.94%$87MNo change
Rubric Capital Management LP8.54M8.60%$68.4M+7%
Orbimed Advisors LLC8.29M8.35%$66.4MNo change
Deerfield Management Company, L.P.7.50M7.56%$60.1MNo change
BlackRock, Inc.5.31M5.35%$42.5M+6%
Tyro Capital Management LLC4.46M4.49%$35.7M+50%
Aberdeen Group plc4.17M4.20%$33.4M+1%
SR One Capital Management, LP4.01M4.04%$32.1MNo change
State Street Corp3.73M3.76%$29.9M+2%
Capital World Investors2.75M2.77%$22.1M–
Vanguard Capital Management LLC2.55M2.57%$20.5M+0%
Millennium Management LLC2.40M2.42%$19.2M-60%
Janney Montgomery Scott LLC2.06M2.08%$16.5M+2%
UBS Group AG1.94M1.95%$15.5M-14%
Geode Capital Management, LLC1.70M1.71%$13.6M+11%
Boothbay Fund Management, LLC1.60M1.61%$12.8M+539%
General American Investors Co Inc1.13M1.14%$9.1M+56%
Third Point LLC1.00M1.01%$8MNo change
Peregrine Capital Management LLC672,1390.68%$5.4M–
Tejara Capital Ltd607,0390.61%$4.9M+189%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, SPRY insiders reported $0 of open-market purchases and $284K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$284K
2 trades, 2 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Jun 12, 2026
Filed Jun 12, 2026

Purchases and sales by month

$284K$284KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 12, 2026Eric KarasChief Commercial OfficerSale plan25,000$10.00$250KForm 4
Jun 12, 2026Alexander A FitzpatrickChief Legal OfficerSale plan3,355$10.00$33.5KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Eric KarasChief Commercial Officer–$250KJun 12, 2026
Alexander A FitzpatrickChief Legal Officer–$33.5KJun 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SPRY short interest

High short interest. 19.1% of SPRY shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went down 27%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 18.99M SPRY shares were sold short, 19.1% of the shares outstanding, down 4.2% from the report before. At the average daily volume of 1.71M shares, buying them all back would take about 11.1 trading days (days to cover).

Shares short, % of all shares

19.1%May 15Oct 3027.1%

Days to cover

11.1May 15Oct 3019.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202618.99M19.10%-4%1.71M11.1
Oct 15, 202619.82M19.93%-6%1.58M12.6
Sep 30, 202621.19M21.31%-8%1.32M16.1
Sep 15, 202623.07M23.20%-1%1.49M15.5
Aug 31, 202623.21M23.34%+1%1.64M14.1
Aug 14, 202622.95M23.08%+7%2.08M11.0
Jul 31, 202621.45M21.60%-5%2.76M7.8
Jul 15, 202622.67M22.83%+4%1.48M15.3
Jun 30, 202621.73M21.89%-6%2.54M8.6
Jun 15, 202623.09M23.25%-9%1.31M17.6
May 29, 202625.50M25.68%-2%1.81M14.1
May 15, 202625.91M26.10%-1%1.95M13.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

ARS Pharmaceuticals company events

ARS Pharmaceuticals filed 8 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Aug 13, 2026ResultsReleased financial results. Filing
  3. Jul 17, 2026LeadershipRichard Lowenthal resigned as a member of the Board of Directors of ARS Pharmaceuticals, Inc., effective immediately. Filing
  4. Jul 7, 2026LeadershipThe Board of Directors of ARS Pharmaceuticals, Inc. appointed the Company’s current President Donn Casale as the Company’s Chief Executive Officer, effective immediately, replacing Richard Lowenthal in such capacity. Filing
  5. Jun 25, 2026VoteReported shareholder vote results. Filing
  6. May 15, 2026ResultsReleased financial results. Filing
  7. May 13, 2026LeadershipThe Board of Directors of ARS Pharmaceuticals, Inc., a Delaware corporation, based in part on the recommendation of Richard Lowenthal, the Company’s Chief Executive Officer, appointed Donn Casale as the Company’s President effective as of the date he commences employment with the Company, which… Filing
  8. Mar 9, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

ARS Pharmaceuticals financials

Famous investors that hold SPRY

5 of the 50 well-known investors we track reported holding SPRY in their latest 13F filing. The largest position is Israel Englander's, worth $14.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20263.27M$14.1M0.0%+36%
Ken Griffin · Citadel AdvisorsQ3 20261.08M$4.6M0.0%+103%
Dan Loeb · Third PointQ3 20261.00M$4.3M0.1%No change
Jim Simons · Renaissance TechnologiesQ3 2026174,200$751K0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202645,895$198K0.0%No change

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about ARS Pharmaceuticals, Inc. (SPRY) stock

Who owns the most SPRY stock?

The largest reported owner of ARS Pharmaceuticals, Inc. (SPRY) is Ra Capital Management, L.P., with 10.9% of the company. In total, 205 funds and institutions reported holding SPRY at the end of Q2 2026, together about 92% of the shares. See the largest owners.

Are SPRY insiders buying or selling?

In the last 12 months, SPRY insiders reported no open-market purchases and 2 sales worth $284K. The latest trade was on Jun 12, 2026. See every trade.

What is the short interest in SPRY?

As of Oct 30, 2026, 18.99M SPRY shares were sold short, 19.1% of the shares outstanding, down 4.2% from the report before. At the average daily volume of 1.71M shares, buying them all back would take about 11.1 trading days (days to cover). See the history.

Which famous investors hold SPRY?

5 of the 50 well-known investors we track reported SPRY in their latest 13F filing, including Israel Englander, Ken Griffin, Dan Loeb. The largest position is worth $14.1M. See all holders.

Executive pay

ARS Pharmaceuticals's chief executive was paid a total of $9.7M for the year ended Dec 31, 2025, up 35% from $7.2M the year before. In the last 12 months, ARS Pharmaceuticals's executives and directors bought no stock on the open market and sold $284K.

Chief executive, total pay$9.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$10.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$4.1MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.